Abstract
Uncontrolled inflammation is a salient factor in multiple chronic inflammatory diseases and cancers. In this review, we provided an in-depth analysis of the relationships and distinctions between uncontrolled inflammation, fibrosis and cancers, while emphasizing the challenges and opportunities of developing novel therapies for the treatment and/or management of these diseases. We described how drug delivery systems, combination therapy and the integration of tissue-targeted and/or pathways selective strategies could overcome the challenges of current agents for managing and/or treating chronic inflammatory diseases and cancers. We also recognized the value of the re-evaluation of the disease-specific roles of multiple pathways implicated in the pathophysiology of chronic inflammatory diseases and cancers—as well as the application of data from singlecell RNA sequencing in the success of future drug discovery endeavors.
Author supplied keywords
- COX/LOX pathway
- Cancer
- Combinational treatment
- Cystic fibrosis
- Epigenetic regulation
- Fibrosis
- HDACI
- Hepatocellular carcinoma
- Hepatocirrhosis
- Idiopathic pulmonary fibrosis
- Immunotherapy
- Interstitial lung disease
- NF-κB pathway
- Nanoparticle delivery
- Prodrug
- STAT3 pathway
- Structure–activity relationship study
- TGF-β pathway
- Tissue inflammation
- Tissue targeting
Cite
CITATION STYLE
Wu, B., Sodji, Q. H., & Oyelere, A. K. (2022, February 1). Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges. Cancers. MDPI. https://doi.org/10.3390/cancers14030552
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.